Thomas Hardiman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Hardiman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Aadil Khan
Targeted Therapy Team, The Institute of Cancer Research, London, UK
18 shared publications - Alan Melcher
The Institute of Cancer Research, London SW7 3RP, UK
18 shared publications - Andrew Roy McKean
Chester Beatty Laboratories, Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom
18 shared publications - Anita Grigoriadis
The Breast Cancer Now Research Unit, King’s College London, London, UK
18 shared publications - Chunhei Li
Division of Infection and Immunity, School of Medicine, Systems Immunity University Research Institute, Cardiff University, Cardiff, United Kingdom
18 shared publications - David C. Mansfield
Chester Beatty Laboratories, Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom
18 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Summary of Western blot density data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Summary of Western blot density data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Knockdown sequence selection for CXCL12 and proof of modulation of CXCL12 in vitro and in vivo. Primary fibroblasts were modified with lentivirus to overexpress CXCL12 with a FLAG-epitope tag to allow clear detection of CXCL12 at protein level and demonstrate effective silencing at the protein level for candidate short-hairpin CXCL12 sequence selection.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Knockdown sequence selection for CXCL12 and proof of modulation of CXCL12 in vitro and in vivo. Primary fibroblasts were modified with lentivirus to overexpress CXCL12 with a FLAG-epitope tag to allow clear detection of CXCL12 at protein level and demonstrate effective silencing at the protein level for candidate short-hairpin CXCL12 sequence selection.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
CD3 expression across time course and examination of CXCL12 expression after irradiation in primary fibroblasts in vitro.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
CD3 expression across time course and examination of CXCL12 expression after irradiation in primary fibroblasts in vitro.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
RTOG acute effects after 50 Gy/3 Fr and cumulative later RTOG toxicities for LVSCR/PBS/LVOeCXCL12
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
RTOG acute effects after 50 Gy/3 Fr and cumulative later RTOG toxicities for LVSCR/PBS/LVOeCXCL12
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Description of RTOG scoring for Acute and Late Toxicities
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Description of RTOG scoring for Acute and Late Toxicities
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Analysis of metastasis in in vivo samples A) Animals were culled at tumour severity limits per model described in figure 5B. Livers, spleens, lungs and ormental mesenteric tissue were harvested for examination of metastasis. Every 10th and 11th section were stained consecutively for H&E and PanCK and examined for evidence of metastasis. Examples of metastasis are shown B) Animal numbers with metastasis according to treatment group (LVSCR vs LVShCXCL12) (n=5 /group).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Analysis of metastasis in in vivo samples A) Animals were culled at tumour severity limits per model described in figure 5B. Livers, spleens, lungs and ormental mesenteric tissue were harvested for examination of metastasis. Every 10th and 11th section were stained consecutively for H&E and PanCK and examined for evidence of metastasis. Examples of metastasis are shown B) Animal numbers with metastasis according to treatment group (LVSCR vs LVShCXCL12) (n=5 /group).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Flow Cytometry of digested flap tissue: Macrophage subtype at day 90 and T-Cell subtype examination at day 21
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Flow Cytometry of digested flap tissue: Macrophage subtype at day 90 and T-Cell subtype examination at day 21
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Summative Data Table for Differential Gene Expression presented in Figure 4A Heatmap (LVSCR vs. LVShCXCL12 samples)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Summative Data Table for Differential Gene Expression presented in Figure 4A Heatmap (LVSCR vs. LVShCXCL12 samples)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Radiation-induced fibrosis (RIF) is a progressive pathology deleteriously impacting cancer survivorship. CXCL12 is an immune–stromal signal implicated in fibrosis and innate response. We hypothesized that modulation of CXCL12 would phenotypically mitigate RIF. CXCL12 expression was characterized in a rodent model of RIF and its expression modulated by the intravascular delivery of lentiviral vectors encoding small hairpin RNA to silence (LVShCXCL12) or overexpress (LVOeCXCL12) CXCL12. Multimodal fibrotic outcomes were quantified, and flow cytometry and Y-chromosome lineage-tracking studies performed to examine cellular recruitment and activation after radiotherapy. Whole-tissue RNA sequencing was used to examine matrisomal response. MATBIII tumors were engrafted within tissues with differing levels of CXCL12 expression, and tumoral response to RT was evaluated. CXCL12 was upregulated in irradiated fibroblasts demonstrating DNA damage after radiotherapy, which led to the recruitment of CD68+ macrophages. Silencing CXCL12 with LVShCXCL12 demonstrated reduced RIF phenotype as a result of decreased macrophage recruitment. Transcriptomic profiling identified osteopontin (OPN; SPP1) as being highly differentially expressed in LVShCXCL12-treated tissues. Tumors growing in tissues devoid of CXCL12 expression responded better after RT because of reductions in peritumoral fibrosis as a result of decreased CXCL12 and OPN expression at the tumor/normal tissue interface. This was also associated with greater CD8+ T-cell infiltration in tumors with less fibrosis. Antibody-mediated OPN blockade slowed tumor growth by increased intratumoral CD8+ T-cell activation. The CXCL12/OPN axis is an important node of immune/matrisomal cross-talk in the development of fibrosis. Therapeutic manipulation of this axis may offer greater antitumor efficacy while also reducing adverse effects.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Radiation-induced fibrosis (RIF) is a progressive pathology deleteriously impacting cancer survivorship. CXCL12 is an immune–stromal signal implicated in fibrosis and innate response. We hypothesized that modulation of CXCL12 would phenotypically mitigate RIF. CXCL12 expression was characterized in a rodent model of RIF and its expression modulated by the intravascular delivery of lentiviral vectors encoding small hairpin RNA to silence (LVShCXCL12) or overexpress (LVOeCXCL12) CXCL12. Multimodal fibrotic outcomes were quantified, and flow cytometry and Y-chromosome lineage-tracking studies performed to examine cellular recruitment and activation after radiotherapy. Whole-tissue RNA sequencing was used to examine matrisomal response. MATBIII tumors were engrafted within tissues with differing levels of CXCL12 expression, and tumoral response to RT was evaluated. CXCL12 was upregulated in irradiated fibroblasts demonstrating DNA damage after radiotherapy, which led to the recruitment of CD68+ macrophages. Silencing CXCL12 with LVShCXCL12 demonstrated reduced RIF phenotype as a result of decreased macrophage recruitment. Transcriptomic profiling identified osteopontin (OPN; SPP1) as being highly differentially expressed in LVShCXCL12-treated tissues. Tumors growing in tissues devoid of CXCL12 expression responded better after RT because of reductions in peritumoral fibrosis as a result of decreased CXCL12 and OPN expression at the tumor/normal tissue interface. This was also associated with greater CD8+ T-cell infiltration in tumors with less fibrosis. Antibody-mediated OPN blockade slowed tumor growth by increased intratumoral CD8+ T-cell activation. The CXCL12/OPN axis is an important node of immune/matrisomal cross-talk in the development of fibrosis. Therapeutic manipulation of this axis may offer greater antitumor efficacy while also reducing adverse effects.
- Open Access
- 4 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Summary of Western blot density data
- 4 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues
Summary of Western blot density data